Approximately 1 in 5 individuals in the United States alone will experience depression during their lifetime. Current guidelines suggest that monotherapy may be used as initial therapy for major depressive disorder, but what evidence exists suggesting that starting dual anti-depressant therapy may have better outcomes? Join your host, Geoff Wall as he discusses a recent meta-analysis regarding dual therapy in depression.

The GameChanger:

For initial therapy or patients who are non-respondent to previous treatment, dual anti-depressant therapy may have a small, but significant impact on treatment outcomes, specifically treatment efficacy.

Show Segments

00:00 – Introductions

01:19 – Dual Therapy in Depression

11:57 – Which Anti-Depressant Combination?

15:27 – The GameChanger

18:37 – Closing Remarks

Host:
Geoff Wall, PharmD., BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

References and resources:

Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis

Redeem your CPE or CME credit here!

• Pharmacist members
• CME

Need a membership?

• Join for CPE Credit
• Join for CME Credit

Continuing Education Information:

Learning Objectives:

1. Describe which two classes of antidepressants had the highest remission rate when used together in this study
2. Discuss the pros and cons of this meta-analysis including the studies' heterogeneity

Dr. Wall is a member of the Janssen Speaker's Bureau.

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-143-H01-P
Initial release date: 04/4/22
Expiration date: 04/4/2023

For more information https://www.ceimpact.com/podcast